Lung Cancer in Women Treated With Anti-oestrogens anD Inhibitors of EGFR
- Status
- COMPLETED
- Phase
- PHASE2
Clinical Trials Related to Fulvestrant
Related studies linked through entity extraction aliases.
Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer
- Status
- TERMINATED
- Phase
- PHASE2
Retrospective Study Assessment Treatment Response Faslodex®( 500 mg)
- Status
- COMPLETED
- Phase
- N/A
Cabozantinib in Women With Metastatic Hormone-Receptor-Positive Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Participants Resistant to Aromatase Inhibitor Therapy
- Status
- COMPLETED
- Phase
- PHASE2
Fulvestrant in Postmenopausal Patients With Metastatic Breast Cancer
- Status
- COMPLETED
- Phase
- N/A
A Phase 1 Study of LY2835219 In Participants With Advanced Cancer
- Status
- COMPLETED
- Phase
- PHASE1
MK2206 in Combination With Anastrozole, Fulvestrant, or Anastrozole and Fulvestrant in Treating Postmenopausal Women With Metastatic Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE1
BKM120 and Fulvestrant for Treating Postmenopausal Patients With Estrogen Receptor-Positive Stage IV Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE1
Comparing the Efficacy and Tolerability of Fulvestrant 500 mg Versus 250 mg in Advanced Breast Cancer Women
- Status
- COMPLETED
- Phase
- PHASE3
A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
- Status
- TERMINATED
- Phase
- PHASE1
A Study of BYL719 in Adult Patients With Advanced Solid Malignancies, Whose Tumors Have an Alteration of the PIK3CA Gene
- Status
- COMPLETED
- Phase
- PHASE1
Safety and Efficacy of AZD4547 in Combination With Fulvestrant vs. Fulvestrant Alone in ER+ Breast Cancer Patients
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Role of Endogenous Estrogen in Growth-Hormone Regulation in Postmenopausal Women
- Status
- COMPLETED
- Phase
- PHASE1
Fulvestrant With or Without AZD6244 in Treating Patients With Advanced Breast Cancer That Progressed After Aromatase Inhibitor Therapy
- Status
- COMPLETED
- Phase
- PHASE2
Fulvestrant With or Without Bortezomib in Patients With Inoperable Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Study of Faslodex With or Without Concomitant Arimidex Versus Exemestane Following Progression on Non-steroidal Aromatase Inhibitors (NSAI)
- Status
- COMPLETED
- Phase
- PHASE3
A Study, Comparing a Dose-Titration Regimen of Fulvestrant With the Approved Dosing Regimen in Postmenopausal Patients With Hormone-Responsive Advanced Breast Cancer (ABC)
- Status
- UNKNOWN
- Phase
- PHASE2
Anti-Hormone Therapy (With Anastrazole and Fulvestrant) Before Surgery to Treat Postmenopausal Women With Breast Cancer.
- Status
- COMPLETED
- Phase
- PHASE2
Trial of Fulvestrant, MK-0646, and Dasatinib for Metastatic Hormone Receptor-Positive HER2-Negative Breast Cancer
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2